💊 AI develops unnatural proteins; Cancer remnants that CAR-T cleans; Immunodeficiency is all in your genes
#260 | Novartis threatens R&D cuts; Lupin recalls TB drugs, no ifs or buts; No lobster for our guts
Hello, and welcome back to a brand-new week with The Kable. For a change, it was a relatively light weekend we just witnessed.
Over in China, the calendar might be heralding a new year, but the Covid surge continues unabated. Or does it?
After culling companies, jobs, factories, and goodness knows what else, Novartis now says it may have to cull R&D plans. Why? Because the US is planning drug pricing restrictions.
Is it deja vu, or is it fresh news? India's Lupin is recalling generic TB drugs in the US.
And finally, a little bit of economics news to kick off the week. Brazil and Argentina are working on a common currency. Other Latin American nations are also being invited to join in a plan that could create the world’s second-largest currency union. The proposed name for the new currency? Sur.